Affordable Access

deepdyve-link
Publisher Website

Comparative Proteome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteogenomics.

Authors
  • Kwon, Oh Kwang1
  • Ha, Yun-Sok2, 3
  • Lee, Jun Nyung2, 3
  • Kim, Sunjoo4
  • Lee, Hyesuk4
  • Chun, So Young5
  • Kwon, Tae Gyun6, 3
  • Lee, Sangkyu7
  • 1 BK21 Plus KNU Multi-Omics-based Creative Drug Research Team, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea. , (North Korea)
  • 2 Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. , (North Korea)
  • 3 Department of Urology, Kyungpook National University Hospital, Daegu, Republic of Korea. , (North Korea)
  • 4 BK21 Plus Team for Creative Leader Program for Pharmacomics-based Future, Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon, Republic of Korea. , (North Korea)
  • 5 Joint Institute for Regenerative Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea. , (North Korea)
  • 6 Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea [email protected] [email protected] , (North Korea)
  • 7 BK21 Plus KNU Multi-Omics-based Creative Drug Research Team, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea [email protected] [email protected] , (North Korea)
Type
Published Article
Journal
Cancer Genomics & Proteomics
Publisher
International Institute of Anticancer Research
Publication Date
Jan 01, 2019
Volume
16
Issue
4
Pages
273–286
Identifiers
DOI: 10.21873/cgp.20132
PMID: 31243108
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Prostate cancer (PCa) is the most frequent cancer found in males worldwide. The aim of this study was to identify new biomarkers using mutated peptides for the prognosis and prediction of advanced PCa, based on proteogenomics. The tryptic peptides were analyzed by tandem mass tag-based quantitative proteomics. Proteogenomics were used to identify mutant peptides as novel biomarkers in advanced PCa. Using a human database, increased levels of INTS7 and decreased levels of SH3BGRL were found to be associated with the aggressiveness of PCa. Using proteogenomics and a cancer mutation database, 70 mutant peptides were identified in PCa cell lines. Using parallel reaction monitoring, the expression of seven mutant peptides was found to be altered in tumors, amongst which CAPN2 D22E was the most significantly up-regulated mutant peptide in PCa tissues. Altered mutant peptides present in PCa tissue could be used as new biomarkers in advanced PCa. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Report this publication

Statistics

Seen <100 times